Literature DB >> 36136177

Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Ajay Dhakal1, Amanda E D Van Swearingen2, Ruth O'Regan1, Carey K Anders3.   

Abstract

OPINION STATEMENT: Brain metastasis arising from breast cancer is associated with a poor prognosis. Various systemic chemotherapy and targeted therapies which are effective against breast cancer often fail to provide benefits against brain metastasis. This is mainly due to limited penetration of the therapies across the blood-brain barrier, and divergent evolution of brain metastasis compared to the primary tumor. Thus, brain metastasis is typically treated upfront with local therapies, such as surgery and radiation, followed by systemic therapies. Systemic therapies with CNS permeability are favored in patients with brain metastasis. This paper reviews various systemic therapy options for breast cancer brain metastasis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain metastases; Breast cancer; HER2; Leptomeningeal; Systemic therapy; Triple negative

Mesh：

Year:  2022        PMID： 36136177     DOI： 10.1007/s11864-022-01011-w

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  56 in total

1.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

2.  Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.

Authors:  Yi-Jun Kim; Jae-Sung Kim; In Ah Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-03       Impact factor: 4.553

3.  Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.

Authors:  Michael A Vogelbaum; Paul D Brown; Hans Messersmith; Priscilla K Brastianos; Stuart Burri; Dan Cahill; Ian F Dunn; Laurie E Gaspar; Na Tosha N Gatson; Vinai Gondi; Justin T Jordan; Andrew B Lassman; Julia Maues; Nimish Mohile; Navid Redjal; Glen Stevens; Erik Sulman; Martin van den Bent; H James Wallace; Jeffrey S Weinberg; Gelareh Zadeh; David Schiff
Journal:  J Clin Oncol       Date:  2021-12-21       Impact factor: 44.544

4.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.

Authors:  Nils D Arvold; Kevin S Oh; Andrzej Niemierko; Alphonse G Taghian; Nancy U Lin; Rita F Abi-Raad; Meera Sreedhara; Jay R Harris; Brian M Alexander
Journal:  Breast Cancer Res Treat       Date:  2012-09-12       Impact factor: 4.872

5.  Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.

Authors:  Sridhar K Rabindran; Carolyn M Discafani; Edward C Rosfjord; Michelle Baxter; M Brawner Floyd; Jonathan Golas; William A Hallett; Bernard D Johnson; Ramaswamy Nilakantan; Elsebe Overbeek; Marvin F Reich; Ru Shen; Xiaoqing Shi; Hwei-Ru Tsou; Yu-Fen Wang; Allan Wissner
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

6.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:  Priscilla K Brastianos; Scott L Carter; Gad Getz; William C Hahn; Sandro Santagata; Daniel P Cahill; Amaro Taylor-Weiner; Robert T Jones; Eliezer M Van Allen; Michael S Lawrence; Peleg M Horowitz; Kristian Cibulskis; Keith L Ligon; Josep Tabernero; Joan Seoane; Elena Martinez-Saez; William T Curry; Ian F Dunn; Sun Ha Paek; Sung-Hye Park; Aaron McKenna; Aaron Chevalier; Mara Rosenberg; Frederick G Barker; Corey M Gill; Paul Van Hummelen; Aaron R Thorner; Bruce E Johnson; Mai P Hoang; Toni K Choueiri; Sabina Signoretti; Carrie Sougnez; Michael S Rabin; Nancy U Lin; Eric P Winer; Anat Stemmer-Rachamimov; Matthew Meyerson; Levi Garraway; Stacey Gabriel; Eric S Lander; Rameen Beroukhim; Tracy T Batchelor; Jose Baselga; David N Louis
Journal:  Cancer Discov       Date:  2015-09-26       Impact factor: 39.397

7.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316

8.  TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Authors:  Rachel A Freedman; Rebecca S Gelman; Carey K Anders; Michelle E Melisko; Heather A Parsons; Anne M Cropp; Kelly Silvestri; Christine M Cotter; Kathryn P Componeschi; Juan M Marte; Roisin M Connolly; Beverly Moy; Catherine H Van Poznak; Kimberly L Blackwell; Shannon L Puhalla; Rachel C Jankowitz; Karen L Smith; Nuhad Ibrahim; Timothy J Moynihan; Ciara C O'Sullivan; Julie Nangia; Polly Niravath; Nadine Tung; Paula R Pohlmann; Robyn Burns; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin
Journal:  J Clin Oncol       Date:  2019-03-12       Impact factor: 44.544

9.  Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.

Authors:  Amélie Darlix; Guillaume Louvel; Julien Fraisse; William Jacot; Etienne Brain; Marc Debled; Marie Ange Mouret-Reynier; Anthony Goncalves; Florence Dalenc; Suzette Delaloge; Mario Campone; Paule Augereau; Jean Marc Ferrero; Christelle Levy; Jean-David Fumet; Isabelle Lecouillard; Paul Cottu; Thierry Petit; Lionel Uwer; Christelle Jouannaud; Marianne Leheurteur; Véronique Dieras; Mathieu Robain; Michaël Chevrot; David Pasquier; Thomas Bachelot
Journal:  Br J Cancer       Date:  2019-11-13       Impact factor: 7.640

10.  Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

Authors:  Cristina Saura; Mafalda Oliveira; Yin-Hsun Feng; Ming-Shen Dai; Shang-Wen Chen; Sara A Hurvitz; Sung-Bae Kim; Beverly Moy; Suzette Delaloge; William Gradishar; Norikazu Masuda; Marketa Palacova; Maureen E Trudeau; Johanna Mattson; Yoon Sim Yap; Ming-Feng Hou; Michelino De Laurentiis; Yu-Min Yeh; Hong-Tai Chang; Thomas Yau; Hans Wildiers; Barbara Haley; Daniele Fagnani; Yen-Shen Lu; John Crown; Johnson Lin; Masato Takahashi; Toshimi Takano; Miki Yamaguchi; Takaaki Fujii; Bin Yao; Judith Bebchuk; Kiana Keyvanjah; Richard Bryce; Adam Brufsky
Journal:  J Clin Oncol       Date:  2020-07-17       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.